Amlodipine improves endothelial function and metabolic parameters in patients with hypertension.

Article Details

Citation

Copy to clipboard

Koh KK, Han SH, Ahn JY, Chung WJ, Lee Y, Shin EK

Amlodipine improves endothelial function and metabolic parameters in patients with hypertension.

Int J Cardiol. 2009 Mar 20;133(1):23-31. doi: 10.1016/j.ijcard.2007.11.058. Epub 2008 Jan 15.

PubMed ID

18199500 [ View in PubMed

]

Abstract

BACKGROUND: Reciprocal relationships between endothelial dysfunction and insulin resistance imply that improvement in endothelial dysfunction will have beneficial metabolic consequences. We hypothesized that amlodipine therapy in hypertensive subjects will improve endothelial dysfunction and metabolic parameters. METHODS: Amlodipine (10 mg daily for 8 weeks) or placebo was given to each 45 patients with mild to moderate hypertension in a randomized, double-blind, placebo-controlled, and parallel study. Age, sex, and body mass index were matched. RESULTS: Amlodipine therapy significantly reduced systolic and diastolic blood pressure and increased HDL-cholesterol to greater extent than placebo therapy (all P<0.001). Amlodipine therapy significantly improved flow-mediated dilator response to hyperemia and reduced plasma malondialdehyde levels to a greater extent than placebo (P<0.001 and P=0.035). Amlodipine therapy significantly increased plasma adiponectin levels (P=0.009) and decreased plasma leptin and resistin levels (P<0.001 and P=0.025, respectively) to a greater extent than placebo. Correlations were noted between percent changes in adiponectin levels and percent changes in HDL-cholesterol (r=0.348, P=0.019) and QUICKI (r=0.326, P=0.029) following amlodipine therapy. Only changes in HDL-cholesterol (beta=0.469, P=0.019) and QUICKI (beta=1.786, P=0.069) were independent predictors of changes in adiponectin levels (multivariate regression analysis). We also observed inverse correlations between percent changes in leptin levels and percent changes in QUICKI (r=-0.569, P<0.001) following amlodipine therapy with changes in QUICKI (beta=1.810, P<0.001) as an independent predictor of changes in leptin levels. CONCLUSIONS: Amlodipine therapy improves blood pressure, endothelial function, and metabolic parameters in patients with hypertension.

DrugBank Data that Cites this Article

Pharmaco-metabolomics

Drug	Drug Groups	Metabolite	Change	Description
Amlodipine	Approved	Malondialdehyde	decreased	Amlodipine decreases the level of Malondialdehyde in the blood
Amlodipine	Approved	HDL cholesterol	increased	Amlodipine increases the level of HDL cholesterol in the blood

Pharmaco-proteomics

Drug	Drug Groups	Gene	Gene ID	Change	Interaction	Chromosome
Amlodipine	Approved	LEP	3952	decreased	Amlodipine results in decreased expression of LEP protein	7q32.1
Amlodipine	Approved	RETN	56729	decreased	Amlodipine results in decreased expression of RETN protein	19p13.2
Amlodipine	Approved	ADIPOQ	9370	increased	Amlodipine results in increased expression of ADIPOQ protein	3q27.3